Polaryx Therapeutics Overview
- Year Founded
-
2014
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
PLYX
- Share Price
-
$1.32
- (As of Friday Closing)
Polaryx Therapeutics General Information
Description
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Contact Information
Website
www.polaryx.comCorporate Office
- 140 East Ridgewood Avenue, South Tower
- Suite 415
- NJ 07652
- United States
Corporate Office
- 140 East Ridgewood Avenue, South Tower
- Suite 415
- NJ 07652
- United States
Polaryx Therapeutics Stock Performance
As of 20-Nov-2026, Polaryx Therapeutics’s stock price is $1.32. Its current market cap is $66.3M with 49.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.32 | $1.51 | $1.30 - $48.91 | $66.3M | 49.8M | 37.7K | -$0.18 |
Polaryx Therapeutics Financials Summary
As of 30-Sep-2026, Polaryx Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 91,639 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (8,747) | (8,985) | (30,356) | (3,779) |
| Net Income | (8,747) | (8,985) | (30,356) | (3,779) |
| Total Assets | 8,610 | 5,170 | 5,001 | 2,315 |
| Total Debt | 128 |
Polaryx Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Polaryx Therapeutics Patents
Polaryx Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260027048-A1 | Gemfibrozil formulation | Pending | 03-Jun-2022 | ||
| WO-2023235541-A1 | Gemfibrozil formulation | Inactive | 03-Jun-2022 | ||
| AU-2021224133-A1 | Gemfibrozil formulation | Active | 19-Feb-2020 | ||
| AU-2021224133-B2 | Gemfibrozil formulation | Active | 19-Feb-2020 | ||
| CA-3168470-A1 | Gemfibrozil formulation | Pending | 19-Feb-2020 | A61K31/192 |
Polaryx Therapeutics Signals
Polaryx Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Polaryx Therapeutics FAQs
-
When was Polaryx Therapeutics founded?
Polaryx Therapeutics was founded in 2014.
-
Where is Polaryx Therapeutics headquartered?
Polaryx Therapeutics is headquartered in NJ.
-
What is the size of Polaryx Therapeutics?
Polaryx Therapeutics has 11 total employees.
-
What industry is Polaryx Therapeutics in?
Polaryx Therapeutics’s primary industry is Drug Discovery.
-
Is Polaryx Therapeutics a private or public company?
Polaryx Therapeutics is a Public company.
-
What is Polaryx Therapeutics’s stock symbol?
The ticker symbol for Polaryx Therapeutics is PLYX.
-
What is the current stock price of Polaryx Therapeutics?
As of 20-Nov-2026 the stock price of Polaryx Therapeutics is $1.32.
-
What is the current market cap of Polaryx Therapeutics?
The current market capitalization of Polaryx Therapeutics is $66.3M.
-
What is Polaryx Therapeutics’s annual earnings per share (EPS)?
Polaryx Therapeutics’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process